A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Astellas Pharma Inc
Therapeutic Advances in Childhood Leukemia Consortium
Masonic Cancer Center, University of Minnesota
Center for International Blood and Marrow Transplant Research
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Arog Pharmaceuticals, Inc.
Children's Oncology Group
Arog Pharmaceuticals, Inc.
University of Nebraska
M.D. Anderson Cancer Center
University of Washington
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Goethe University
Goethe University
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Goethe University
Children's Oncology Group
University of Washington
University of Washington
H. Lee Moffitt Cancer Center and Research Institute
Stanford University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
Pfizer
M.D. Anderson Cancer Center
Array BioPharma
Masonic Cancer Center, University of Minnesota
PETHEMA Foundation
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
PETHEMA Foundation
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
University of Pittsburgh
M.D. Anderson Cancer Center
Swiss Cancer Institute
Nohla Therapeutics, Inc.
Pfizer
Cellerant Therapeutics